Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
about
P1343
Rhythmic binding of Topoisomerase I impacts on the transcription of Bmal1 and circadian periodSUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damageTopotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase IThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorDNA topoisomerase-targeting antitumor drugs can be studied in yeastDesign, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2.Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex ligands as antitumor agents.Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Identification of a topoisomerase I mutant, scsA1, as an extragenic suppressor of a mutation in scaA(NBS1), the apparent homolog of human nibrin in Aspergillus nidulans.Transcription-dependent degradation of topoisomerase I-DNA covalent complexesCharacterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin.Topoisomerase I is preferentially associated with normal SV40 replicative intermediates, but is associated with both replicating and nonreplicating SV40 DNAs which are deficient in histones.A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group.In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer.Inhibition of retrovirus-induced disease in mice by camptothecin.Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks.The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cellsTopoisomerase I is preferentially associated with isolated replicating simian virus 40 molecules after treatment of infected cells with camptothecin11-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridine derivatives as novel topoisomerase I-targeting agents.Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents.Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.New natural products in cancer chemotherapy.Macrocyclic pyridyl polyoxazoles: structure-activity studies of the aminoalkyl side-chain on G-quadruplex stabilization and cytotoxic activity.A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay.Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.Biochemical changes in testicular varicocele.Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.Topoisomerase I inhibitors and drug resistanceCamptothecin enhances the frequency of oligonucleotide-directed gene repair in mammalian cells by inducing DNA damage and activating homologous recombination.Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells.
P2860
Q24297026-FD014D75-0B3A-4A33-A632-ADAE1882100CQ24682811-BD26DB2E-E53F-450E-9174-2300179E3187Q28378884-B6687B4C-BBD9-49E7-BB37-C5580173F63DQ33500497-EB4CAD9A-D8A4-4ADD-B6B1-F6CE673F90BEQ33654182-AE5563D4-128B-42C8-99A9-CD2B6D4EE764Q33662415-AEDEBCC0-DE3A-495E-B0AA-30B2BA8C9340Q33677099-20BE7D8F-E21C-483E-821A-2C89E48244A7Q33833531-DA3BA792-3B9B-4C7D-A475-D09536BBD1EEQ33856425-29EA053E-A495-49D8-B39E-76ACA79E54ACQ33923420-41819871-3B94-4C97-B3E0-796D8E13A5AAQ33925798-D515C37F-A382-4E94-B2BA-08774DC7A385Q34617988-ABA26E61-B101-4BCA-B599-434939BB5115Q34784817-1EAD9A48-0799-458E-98B1-8CD8B91F6892Q34967081-F33A91B3-CB41-4450-93B1-EB7F3E910588Q35020099-7D307B78-49D7-47F0-B563-04D5B307640DQ35072982-7841529E-6DD6-4ABA-9481-DF68CB789AD6Q36114656-4C13BC0C-B7E4-4B7B-9B7D-A567DC33F8A4Q36116478-35D86D87-BC54-45BE-868B-C688D1790A29Q36292082-6A3DAF4C-D0FE-44B4-A692-064F3006BAA9Q36293009-E2124ACC-A98D-44FD-8CF1-1340FB1FE162Q36431807-8E77BF40-A85D-4AB2-A7EB-E96A078B5BA7Q36619185-95182937-4E88-4213-A21D-3F63BD5F68D2Q36648965-CEB93795-13C1-49BE-B315-46821566104FQ36792502-48D66E12-F744-4DB9-8B53-D3FD988A3DECQ36797222-C3B09691-A0B0-4FE2-8221-58B220E0019AQ36872974-6723826B-9B1A-4880-B1DF-8CFBAA384015Q37323423-962D4C5B-7244-442D-A4F1-EEAC29270E5BQ37363590-D1A41C03-2FE2-4792-9AA5-D8892C21D819Q37363598-D9C00DD0-CE60-4087-93C3-96DF330343BBQ37396799-D0A3A7FD-7625-4A32-B3FB-6334C8F95C8EQ37608749-1CE882A3-ABA0-4A54-839C-96E4B48D53FBQ37630342-6E5C6331-020E-47D0-9C0A-A8218B38D3D1Q38318734-C87D425A-4D24-45D1-83E6-3CE5052A9805Q38350593-2BF3FEEB-1A04-4F6F-8F1F-19DBC802A269Q38666261-92C009D2-E94D-44C2-A230-2322B8A1330CQ39171279-755E684E-1A72-4974-B5C1-E734034FE386Q40028536-2341425E-9F38-4BCB-8F29-DE286528B061Q40156233-C44B9627-AC1B-474A-B30B-8A86DE0337CEQ40308617-700F34DA-3E38-4184-A84F-96501CAF7745Q40514331-49CE83BC-C3ED-4E3A-87A9-744DC79809EC
P2860
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
description
1987 nî lūn-bûn
@nan
1987 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@ast
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@en
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@nl
type
label
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@ast
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@en
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@nl
prefLabel
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@ast
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@en
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@nl
P2093
P2860
P356
P1476
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
@en
P2093
Kusunoki Y
Takemoto Y
P2860
P304
P356
10.1073/PNAS.84.16.5565
P407
P4510
P577
1987-08-01T00:00:00Z